Related Experiment Video
Updated: May 21, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Foot sarcomas: Factors affecting oncological and functional outcomes
Eiji Kozawa1, Yoshihiro Nishida, Hiroatsu Nakashima
1Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550.
Oncology Letters
|June 29, 2012
Summary
Identifying prognostic factors for foot sarcomas is crucial. Larger tumor size, amputation, and bone reconstruction negatively impact oncological and functional outcomes, suggesting a need for multimodal treatment strategies.
Area of Science:
- Orthopedic Oncology
- Surgical Oncology
- Sarcoma Research
Background:
- Prognostic factors for foot sarcomas remain unclear.
- Understanding these factors is essential for optimizing oncological and functional outcomes.
Purpose of the Study:
- To identify prognostic factors for oncological and functional outcomes in foot sarcoma patients.
- To evaluate the role of adjuvant radiotherapy in local control.
Main Methods:
- Retrospective review of 31 consecutive foot sarcoma patients (24 soft tissue, 7 bone).
- Analysis of patient characteristics, tumor size, surgical treatment (amputation, limb salvage, reconstruction), and adjuvant radiotherapy.
- Assessment of oncological (local recurrence, metastasis) and functional outcomes.
Main Results:
- Amputation was a significant poor prognostic factor for oncological outcomes (p=0.002).
- Larger size and bone reconstruction were associated with poorer local recurrence-free survival and metastasis-free survival in soft tissue sarcomas.
- Larger size, amputation, and bone reconstruction negatively affected function in soft tissue sarcomas; hindfoot site and amputation impacted function in bone sarcomas.
Conclusions:
- Surgery with negative margins and reconstructive procedures are key for local control and function.
- Foot sarcoma patients with larger tumors, requiring amputation or bone reconstruction, need novel multimodal treatment approaches for improved outcomes.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...